Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
तुलना करने के लिए मीट्रिक्स | NVAX | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNVAXपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −6.9x | −4.1x | −0.5x | |
PEG अनुपात | −0.09 | −0.06 | 0.00 | |
क़ीमत/बुक | −2.1x | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1.9x | 10.2x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 38.3% | 56.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 12.8% | 10.1% | अनलॉक करें |